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ATP-triggered anticancer drug delivery
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Stimuli-triggered drug delivery systems have been increasingly used to promote physiological
specificity and on-demand therapeutic efficacy of anticancer drugs. Here we utilize
adenosine-5’-triphosphate (ATP) as a trigger for the controlled release of anticancer drugs.
We demonstrate that polymeric nanocarriers functionalized with an ATP-binding
aptamer-incorporated DNA motif can selectively release the intercalating doxorubicin via a
conformational switch when in an ATP-rich environment. The half-maximal inhibitory
concentration of ATP-responsive nanovehicles is 0.24 mM in MDA-MB-231 cells, a 3.6-fold
increase in the cytotoxicity compared with that of non-ATP-responsive nanovehicles.
Equipped with an outer shell crosslinked by hyaluronic acid, a specific tumour-targeting
ligand, the ATP-responsive nanocarriers present an improvement in the chemotherapeutic
inhibition of tumour growth using xenograft MDA-MB-231 tumour-bearing mice. This
ATP-triggered drug release system provides a more sophisticated drug delivery system,
which can differentiate ATP levels to facilitate the selective release of drugs.
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N
anocarrier-based drug delivery systems (DDSs) offer new
opportunities to improve bioactivity and prolong bioa-
vailability of drugs for cancer therapy1–4. To further
enhance biological specificity and therapeutic efficacy, significant
efforts have been devoted to explore active targeting5 and stimuli-
responsive DDSs6, which specifically accumulate at the tumour
site and are stimulated to release drugs within tumour cells. These
stimuli can be a variety of external signals, such as temperature7,
light8, magnetic field9, ultrasound10 and electric current11, as
well as physiological factors, such as pH12, redox potential13,
enzymatic activities14,15 and glucose levels16,17. A number of
nanosystems including liposomes18, polymeric nanoparticles19
and inorganic particles20 have been developed to apply these
triggering cues to tailor pharmacokinetics and enhance delivery
efficiency. For example, acid-sensitive species have been widely
incorporated in intracellular delivery vehicles that undergo an
endocytosis pathway, thereby allowing drugs to be readily
released in acidic compartments12. The gradient of reduced
glutathione enables polymeric nanogels crosslinked with
glutathione-cleavable disulphides to efficiently release payloads
inside cells21. The proteases highly expressed in specific tumour
microenvironments facilitate nanocarriers consisting of relevant
peptidyl substrates to release drugs on demand14.
In this study, we report that ATP, the most abundant
ribonucleotide used in cells as a coenzyme, can serve as a new
trigger for the controlled release of anticancer drugs both in vitro
and in vivo. As the ‘molecular unit of currency’ of intracellular
energy transfer, ATP transports chemical energy within cells to
support metabolism22. ATP is present in low concentrations
(o0.4mM) in the extracellular environment, but is relatively
concentrated within the intracellular cytosol (1–10mM)23–26.
Within cells, ATP provides energy to the cellular metabolism by
breaking a phosphoanhydride bond. The prominent difference in
the ATP level between the extracellular and intracellular
environments is the biological rationale for design of ATP-
mediated drug release systems, which remain elusive27. Recently,
Biswas et al.28 applied the hydrolysis of intracellular ATP into
ADP to trigger conformational variation of the chaperonin units
in the supramolecular nanotubes, which subsequently caused the
disassembly of the tubes and release of the guests. Using a
different strategy, we envision that ATP-responsive nanosystems
can be functionalized with ATP-binding aptamers, which are
specifically recognized and activated by ATP and directly
promote the release of preloaded anticancer drugs. The nano-
carriers can selectively release the drug via a conformational
switch under an ATP-rich environment for enhanced cytotoxicity
and apoptosis. On a combination of passive and active
targeting effects, the system presents an improvement in the
chemotherapeutic inhibition of tumour growth in mice.
We designed a nanocarrier comprised of DNA, protein and
polysaccharide. As shown in Fig. 1a, the final formulation
(designated nanogel) is mainly comprised of three distinct
functional constituents: an ATP-responsive DNA motif with
doxorubicin (Dox), protamine and a hyaluronic acid (HA)-
crosslinked shell. The DNA scaffold consists of the ATP aptamer
and its complementary single-stranded DNA (cDNA), the
structure of which has been previously used to detect ATP29–32.
The GC pairs of the DNA motif provide faithful loading sites for
Dox, a model chemotherapeutic drug used to treat a wide
spectrum of cancers, including breast cancer, ovarian cancer and
acute leukaemia. In the presence of ATP, the tertiary structure of
the ATP aptamer is stabilized, which causes the DNA duplex to
dissociate and thereby liberates cDNA. In our strategy, this
structural change from the duplex to the tertiary aptamer
structure (duplex-to-aptamer) results in the intercalated Dox to
be released from the duplex (Fig. 1b). Protamine is positively
charged and is applied to compress the negatively charged DNA
scaffold into a cationic core complex, which has enhanced cell
penetration, endosomal escape and nuclear targeting effects33.
Anionic HA is coated on the core complex to form a protective
shell, and also supports active tumour-targeting ligands to
bind the receptors, such as CD44 and RHAMM, which are
overexpressed on the cell surface of several tumours34. In
addition, hyaluronidase (HAase)35, rich in various malignant
tumour matrices and the tumour cellular endocytic vesicles
including endosomes and lysosomes (endolysosomes)36, leads to
the degradation of the HA shell and allows the exposure of the
cationic complex to facilitate intracellular delivery. To obtain
the compact ‘gel’ structure37, protamine and HA are modified
with acrylamide (designated m-protamine) and acrylate groups
(designated m-HA), respectively. The final nanogels are
constructed by photocrosslinking via UV irradiation.
After intravenous injection, the nanogel is expected to
accumulate at tumour sites as a result of passive and active
targeting effects. HAase degrades the HA shell, thereby exposing
the complex of protamine with the Dox-intercalated duplex
(Dox/Duplex). The protamine component promotes endosomal
escape of the complex, allowing the efficient transport of Dox/
Duplex into the cytosol. Dox/Duplex dissociates at a significantly
higher ATP level in the cytosol compared with the extracellular
fluid, thereby yielding the release of intercalating Dox, which
eventually accumulates in the nuclei to produce cytotoxicity and
apoptosis (Fig. 1c). This ATP-triggered drug release system offers
new avenues for exploration of more sophisticated DDSs, which
integrates with tumour metabolism for controlled release of
anticancer drugs.
Results
ATP-triggered Dox release from duplex. We first designed a
DNA scaffold by hybridizing an ATP aptamer and its cDNA
(Supplementary Table 1, Supplementary Methods), which has a
27-base pair with GC-rich motif for anthracycline-contained Dox
loading38. To evaluate the amount of Dox molecules loaded into
the ATP-Duplex, we measured Dox intercalation by monitoring
Dox fluorescence intensity changes. When a fixed concentration
of Dox was incubated with an increasing molar ratio of the DNA
duplex, a sequential decrease was found in the fluorescence
intensity of Dox (Fig. 2a) due to the initiation of förster resonance
energy transfer between Dox molecules when intercalated into the
DNA duplex39,40. A maximum quenching efficacy was achieved
when the molar ratio of duplex to Dox was 0.5. To investigate
the ATP-responsive characteristics of the duplex, Dox/Duplex
was incubated at 0.4mM and 4mM ATP concentrations,
which represent the typical ATP level in the extracellular fluid
and intracellular cytosol, respectively23–26. The dissociation of
Dox/Duplex leads to the release of Dox, which can be estimated
by detecting the recovery of the Dox fluorescence. As shown in
Fig. 2b, a remarkable fluorescence recovery was observed in
the presence of 4mM ATP concentration compared with the
0.4mM sample, indicating that Dox/Duplex is responsive to
high concentrations of ATP. The fluorescence recovery ratio
((FNTP-F)/(F0 F)) showed that the Dox release from Dox/
Duplex was ATP-concentration dependent (Fig. 2c), where F0 is
the fluorescence intensity of Dox in the Dox solution without the
duplex, and FNTP and F are the fluorescence intensities of Dox
in Dox/Duplex at the same Dox concentration as in the Dox
solution in the presence and absence of ATP, respectively.
The fluorescence recovery ratio was determined as 20 and 31%
at ATP concentrations of 2 and 4mM, about fourfold and
sevenfold greater than that at an ATP concentration of 0.4mM,
respectively. In contrast, negligible changes were found in the
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fluorescence recovery ratio of Dox/Duplex after incubation with
the analogues of ATP such as cytidine triphosphate, guanosine
triphosphate and uridine triphosphate, suggesting that the ATP
aptamer-functionalized Dox/Duplex had a good selectivity to
ATP compared with its analogues, which were unable to release
Dox even at high levels. Furthermore, we took Dox-loaded
control duplex (Dox/cDuplex)31 that had the same length but was
not responsive to ATP as a reference (Supplementary Table 1 and
Supplementary Fig. 1). The fluorescence recovery ratio of
Dox/Duplex was about fivefold of that of Dox/cDuplex in the
presence of a 4mM ATP concentration (Fig. 2d), substantiating
that the ATP aptamer endowed Dox/Duplex with the ATP-
responsive drug release capability. Taken together, Dox/Duplex,
the ATP-responsive DNA motif encapsulating Dox, can be used
to effectively release Dox via a duplex-to-aptamer structural
change under elevated ATP concentrations, which provides a
foundation for the construction of an ATP-responsive DDS.
Preparation and characterization of ATP-responsive nanogels.
Dox/Duplex was mixed with m-protamine at an optimal mass
ratio of 14:17 to prepare a positively charged Dox-loaded com-
plex41 (Dox/Complex) (Fig. 3a and Supplementary Fig. 2). The
complex was then added to the m-HA solution at a mass ratio of
m-HA to m-protamine as 1:1 to obtain an HA-coated Dox/
Complex (Dox/HA-Complex) with a negative charge (Fig. 3b and
Supplementary Figs 3 and 4). Ultimately, Dox-loaded nanogel
(Dox/NG) was obtained by photocrosslinking Dox/HA-Complex
with an acid-labile crosslinker glycerol dimethacrylate (GDA).
Insignificant influence on the ATP response of Dox/Duplex was
found after a short period of UV exposure (Supplementary
Fig. 5). The fluorescence of Dox was still quenched in the
obtained Dox/NG (Supplementary Fig. 6). As shown in Fig. 3c,
the changes in the particle size and zeta potential from Dox/
Duplex to Dox/NG suggested an efficient HA coating of the
complex and the synthesis of Dox/NG, which had a resulting
particle diameter of about 160 nm with a polydispersity index of
0.144 (Supplementary Fig. 7) and a zeta potential of –20mV.
Transmission electron microscope (TEM) imaging further
confirmed a spheroid structure of Dox/NG with a uniform
particle size of about 150 nm (Fig. 3d).
To evaluate ATP-triggered Dox release characteristics, we
investigated in vitro release profiles of Dox from Dox/NG in the
presence and absence of ATP at 37 C. Both Dox/NG and non-
ATP-responsive Dox-loaded control nanogel (Dox/cNG), which
consisted of the same components with Dox/NG except Dox/
cDuplex, presented a sustained Dox release compared with the
Dox solution (Fig. 3e). More importantly, in the presence of
0.4mM ATP, only 6% of Dox was released from Dox/NG in the
first 4 h and B20% was released within 24 h. In the same buffer
solution with 4mM ATP, a level comparable to intracellular ATP
levels, the release of Dox was dramatically accelerated. About 20%
of Dox was released from Dox/NG in the first 4 h and more than
40% was released within 24 h. It is also noteworthy that the
release of Dox from Dox/cNG (without ATP sensitivity) was
slow even in the presence of 4mM ATP. It is therefore implied
that the ATP aptamer is essential for Dox/NG to recognize ATP
concentration and allow the fast release of the intercalated
Dox molecules in ATP-rich environments, and Dox remains
entrapped in the inner cores of Dox/NG at low ATP
concentrations.
To demonstrate HA degradation by HAase35, the variation in
the zeta potential of Dox/NG was monitored after incubation
with HAase at different pH values over time. As shown in Fig. 3f,
the zeta potential of Dox/NG sharply changed from highly
negative (–23mV) to less negative (–6mV) after exposure to
HAase for 2 h at pH 7.4. Moreover, the HA shell of Dox/NG
crosslinked by GDA showed a pH-dependent degradation.
Higher acidities had a concomitant enhancement on the
degradation of the shell of Dox/NG. At 2 h, the zeta potential
of Dox/NG continuously rose to þ 3mV at pH 6.0 and þ 6mV
at pH 5.0, while Dox/NG still presented slightly negative charge
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Figure 1 | Schematic design of the ATP-triggered Dox release system. (a) The main components of Dox/NG: ATP-responsive DNA motif with Dox,
protamine and a HA-crosslinked gel shell. (b) Mechanism of ATP-triggered release of Dox based on the structural change of duplex-to-aptamer.
(c) ATP-responsive delivery of Dox by Dox/NG to nuclei for the targeted cancer therapy. I, accumulation of Dox/NG at the tumour site through passive
and active targeting; II, specific binding to the overexpressing receptors on the tumour cells and degradation of HA shell by HAase rich in the tumour
extracellular matrix; III, receptor-mediated endocytosis; IV, endosomal/lysosomal escape; V, ATP-triggered Dox release in the cyotosol; VI, accumulation
of Dox in the nucleus.
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of –6mV at pH 7.4. Accordingly, the crosslinked HA shell of
Dox/NG will be preferentially dissociated in the HAase-rich
acidic tumour microenvironment and intracellular endolysosome
to ‘turn off’ the protective function of HA and ‘turn on’ the
penetrating activity of the protamine-based complex for efficient
intracellular delivery.
Intracellular ATP-triggered Dox release of Dox/NG. We next
investigated whether intracellular ATP could accelerate the
release of Dox determined by the fluorescence recovery of Dox in
the cells. To assess this, the human breast adenocarcinoma
(MDA-MB-231) cells were incubated with Dox/cNG and Dox/
NG for 2 h and the excess nanogels were thoroughly removed.
The cells were then incubated with fresh culture medium for an
additional 2 or 4 h. The amount of released Dox was evaluated by
recording the fluorescence intensity of the whole cells. Dox
fluorescence was observed during the first 2 h of the cellular
uptake of Dox/NG at 37 C (Fig. 4a), which resulted from the
unquenched background fluorescence of Dox and the Dox
released from Dox/NG40. Notably, Dox/NG presented a
concomitant increase of fluorescence intensity with increasing
incubation time of the cells. The fluorescence intensity had 30
and 49% significant increase after an additional 2 h and 4 h of
incubation, respectively. However, the cells incubated with
Dox/cNG showed no evident increase in the Dox fluorescence
intensity. This prominent difference in the fluorescence intensity
between cells incubated with Dox/NG and Dox/cNG suggested
that Dox/NG was able to selectively liberate Dox in a more
efficient manner based on the intracellular ATP level by ATP-
responsive structural changes, relative to Dox/cNG that released
Dox by passive diffusion. To further demonstrate the intracellular
ATP concentration-dependent Dox release from Dox/NG, we
inhibited the ATP production of the cells by physically lowering
the temperature (4 C) and adding a chemical inhibitor,
iodoacetic acid (IAA)42, and subsequently monitored the
fluorescence intensity after the treated cells were incubated with
Dox/NG. Cell incubation at 4 C and with IAA at 37 C both led
to a significant decrease in ATP generation within the cells
(Fig. 4b). As expected, no remarkable release of Dox from Dox/
NG was found in the cells that were incubated at 4 C, nor with
IAA at 37 C for additional 2 h or 4 h (Fig. 4c), further confirming
the intracellular ATP-mediated drug release capability of
Dox/NG.
The intracellular delivery of Dox/NG in MDA-MB-231 cells
was also explored using confocal laser scanning microscopy
(CLSM). Dox/NG was demonstrated to bind to the CD44
receptor on the cell membrane (Supplementary Fig. 8),
followed by internalization via the clathrin-mediated pathway
(Supplementary Fig. 9) and subsequent transportation into the
endosomes and lysosomes43,44. As shown in Fig. 4d, most of the
endocytosed Dox/NG was located in the endolysosomes judged
by the yellow fluorescence during the first 2 h of incubation.
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Figure 2 | ATP-triggered Dox release from duplex. (a) The fluorescence spectra of the Dox solution (1.33mM) with increasing molar ratios of
hybridized DNA duplex of ATP aptamer and its complementary single-stranded DNA (from top to bottom: 0, 0.01, 0.025, 0.05, 0.1, 0.25, 0.5, 1 equiv.)
after 15min of incubation in the HEPES buffer (5mM). (b) The fluorescence spectra of Dox/Duplex (1.33mM) at the molar ratio of duplex to Dox as
0.5 in the presence of different concentrations of ATP (0.2, 0.4, 1, 2, 4, 8mM) after 15min of incubation. (c) Fluorescence recovery ratios of Dox/Duplex
in the presence of different concentrations of ATP, GTP, CTP and UTP (0.2, 0.4, 1, 2, 4, 8mM). Error bars indicate s.d. (n¼ 3). (d) Fluorescence
recovery ratios of Dox/Duplex and Dox/cDuplex in the presence of 4mM ATP. Error bars indicate s.d. (n¼ 3). The fluorescence recovery ratio is indicated
as (FNTP F)/(F0 F), where F0 is the fluorescence intensity of Dox in the Dox solution without the duplex, and FNTP and F are the fluorescence intensities
of Dox in Dox/Duplex at the same Dox concentration with the Dox solution in the presence and absence of NTP, including ATP, CTP, GTP and UTP,
respectively. In (b–d), the buffer and salt condition is the HEPES buffer (5mM) containing 10mM MgCl2 and 137mM NaCl. CTP, cytidine triphosphate;
GTP, guanosine triphosphate; UTP, uridine triphosphate.
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dissociation of the broader red fluorescence and less green
fluorescence suggested the endolysosomal escape of Dox/NG with
the help of protamine, and led to a significant release of Dox
resulting from the high cytosolic ATP level. Furthermore, the
released Dox specifically accumulated into the nuclei, as
evidenced by the magenta fluorescence characteristic of a
cascade in apoptosis.
The in vitro cytotoxicity of Dox/NG against two kinds
of human breast adenocarcinoma cells, specifically MDA-MB-
231 and MCF-7 cells, was evaluated by using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay. Dox/NG presented the significantly enhanced cytotoxicity
compared with Dox/cNG towards both MDA-MB-231 and
MCF-7 cells at all the Dox concentrations studied (Fig. 4e,f).
IC50 of Dox/NG was 0.24 mM on MDA-MB-231 cells and
0.80 mM on MCF-7 cells, which was remarkably lower than that
of Dox/cNG, 1.1 mM on MDA-MB-231 cells and 2.9 mM on
MCF-7 cells, respectively. Dox/NG also showed greater cytotoxi-
city than the Dox solution (IC50¼ 0.30 mM) on MDA-MB-231
cells (Supplementary Fig. 10) and Dox-loaded PEGylated
liposomes (Dox/PEG-L) on both cancer cells (Supplementary
Fig. 11). Blank nanogels without Dox did not show toxicity within
the tested range of concentrations (Supplementary Fig. 12). It was
suggested that the efficient intracellular release of Dox from
Dox/NG compared with Dox/cNG provides higher cytotoxic
activity towards the cancer cells.
Furthermore, to demonstrate that Dox effectively released from
Dox/NG could also induce elevated apoptosis, the Annexin
V-FITC/PI apoptosis detection and the terminal deoxynucleotidyl
transferase dUTP nick end labelling (TUNEL) assay were
performed to compare the apoptosis-inducing capabilities of
Dox/NG and Dox/cNG. Annexin V-FITC labels the phosphati-
dylserine sites that translocates to the extracellular membrane
upon initiation of apoptosis, while PI labels the intracellular DNA
in the late apoptotic cells where the plasma membrane has been
compromised45,46. This combination allows the differentiation
among the early apoptotic cells, the late apoptotic cells and the
viable cells, which can be quantitatively determined by the flow
cytometry47. The total apoptotic ratio of Dox/NG was 56.61%
obtained by summation of the early apoptotic ratio of 39.54% and
the late apoptotic ratio of 17.07%, which was much higher than
38.02% of Dox/cNG (Fig. 4g). In addition, during apoptosis,
caspase 3 cleaves the inhibitor of caspase-activated deoxyribo-
nuclease and produces nucleosomal DNA fragmentation48,
which can be visualized with the TUNEL assay using CLSM49.
MDA-MB-231 cells treated with Dox/NG showed more extensive
apoptotic DNA fragmentation stained by the Alexa Fluor 488
as green fluorescence in comparison with that treated with
Dox/cNG (Fig. 4h). These results confirmed that ATP-responsive
Dox/NG is an effective intracellular nanocarrier delivery system
for enhanced apoptosis-inducing activity.
Tumour targeting and antitumour efficacy of Dox/NG. To
evaluate the tumour targeting capability of Dox/NG, the in vivo
biodistribution of Cy5.5-labelled Dox/NG (Dox/Cy5.5-NG)
administrated intravenously into the MDA-MD-231 tumour-
bearing mice was investigated by a non-invasive near-infrared
optical imaging technique. Dox/Cy5.5-NG presented a stronger
fluorescence signal in the tumour region over a short time
compared with Cy5.5-labelled Dox/Complex (Dox/Cy5.5-
Complex) without the HA shell (Fig. 5a). As time increased,
elevated fluorescence signals of Dox/Cy5.5-NG were found at the
tumour site as compared with the normal tissues within 24 h post
injection, indicating a notable tumour targeting effect of the
nanogels. To further confirm the role of the interaction between
3,000 3,000
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Figure 3 | Characterization of ATP-responsive nanogels. (a) The particle size and zeta potential of Dox/Complex at different mass ratios of
m-protamine and duplex. Error bars indicate s.d. (n¼ 3). (b) The particle size and zeta potential of Dox/HA-Complex at different mass ratios of m-HA
and m-protamine. Error bars indicate s.d. (n¼ 3). (c) The particle size and zeta potential of Dox/Duplex, Dox/Complex and Dox/NG. Error bars
indicate s.d. (n¼ 3). (d) The hydrodynamic size of Dox/NG measured by dynamic light scattering. Inset: TEM image of Dox/NG (accelerating voltage:
80 kV). Scale bars are 100nm (upper) and 500nm (lower). (e) In vitro release of Dox/NG and Dox/cNG at different concentrations of ATP. Error
bars indicate s.d. (n¼ 3). (f) Changes in the zeta potential of Dox/NG incubated with 0.5mgml 1 HAase at different pH values for different time.
Error bars indicate s.d. (n¼ 3).
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Figure 4 | Intracellular ATP-triggered Dox release. (a) Dox released in MDA-MB-231 cells of Dox/NG and Dox/cNG obtained using the flow
cytometry. The cells were incubated with Dox/NG or Dox/cNG at 37 C for 2 h, and subsequently incubated with fresh culture medium at 37 C
for additional 2 h or 4 h after removal of the excess nanogels. Error bars indicate s.d. (n¼ 3). **Po0.01 (two-tailed Student’s t-test). (b) The ATP
content in MDA-MB-231 cells after different treatments. Error bars indicate s.d. (n¼ 3). **P o0.01 compared with the control group (two-tailed Student’s
t-test). (c) Dox released in MDA-MB-231 cells of Dox/NG obtained using the flow cytometry. The cells were incubated with Dox/NG at 37 C for
2 h, and then incubated with the fresh culture medium at 4 C or with IAA at 37 C for additional 2 h or 4 h after removal of the excess
nanogels. Error bars indicate s.d. (n¼ 3). **Po0.01 (two-tailed Student’s t-test). (d) Intracellular delivery of Dox/NG on MDA-MB-231 cells at different
time observed by CLSM. The cells were incubated with Dox/NG at 37 C for 2 h, and further incubated with fresh culture medium at 37 C for additional
4 h after removal of the excess nanogels. The late endosomes and lysosomes were stained by LysoTracker Green, and the nuclei were stained by
Hoechst 33342. Scale bar is 10mm. (e,f) In vitro cytotoxicity of Dox/cNG and Dox/NG on MDA-MB-231 (e) and MCF-7 cells (f) for 24 h. Error bars indicate
s.d. (n¼4). *Po0.05, **Po0.01 (two-tailed Student’s t-test). (g) Flow cytometric analysis of MDA-MB-231 cell apoptosis induced by Dox/cNG and
Dox/NG for 12 h using the Annexin V-FITC/PI staining. In each panel, the lower-left (Annexin V-FITC , PI ), lower-right (Annexin V-FITCþ , PI )
and upper-right (Annexin V-FITCþ , PIþ ) quadrants represent the populations of live cells, early apoptotic cells and late apoptotic cells, respectively.
The average population (%) in each quadrant is indicated by the numbers at the corner of the panels. (h) MDA-MB-231 cell apoptosis induced by
Dox/cNG and Dox/NG for 20 h using the APO-BrdU TUNEL assay. Alexa Fluor 488-stained nick end label showed green fluorescence, and PI-stained
nuclei showed red fluorescence. Scale bar is 100 mm.
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CD44 receptors and HA in this high tumour targetability of the
nanogels, a high dose of free HA was intravenously pre-injected
prior to administration of Dox/Cy5.5-NG to block CD44-
mediated binding of the nanogels on tumour tissue. As expected,
the fluorescence signal of Dox/Cy5.5-NG significantly reduced at
the tumour site after pre-injection of free HA into the mice
(Fig. 5a). After 24 h post injection, the mice were immediately
euthanized, and the tumours as well as normal tissues were
harvested for ex vivo imaging. The fluorescence signal of
Dox/Cy5.5-NG at the tumour site was significantly higher than
that of Dox/Cy5.5-Complex and Dox/Cy5.5-NG pretreated
with free HA (Fig. 5b), which was sextupled and tripled using
quantitative region-of-interest analysis, respectively (Fig. 5c).
In addition, the fluorescence signal at the tumour site was
approximately double than that in the liver or kidney after
injection of Dox/Cy5.5-NG for 24 h (Fig. 5b,c).
We have also evaluated the pharmacokinetics and biodistribu-
tion of the Dox solution, Dox/Complex and Dox/NG after
intravenous injection into the MB-MDA-231 tumour-bearing
mice by quantitatively detecting the Dox amounts in the plasma
and different tissues, including heart, liver, spleen, lung,
kidney and tumour. Dox/NG showed an enhanced blood
persistence compared with the Dox solution and Dox/Complex
(Supplementary Fig. 13). The area under the plasma concentra-
tion versus the time curves, elimination half-life (t1/2) and mean
residence time of Dox/NG were remarkably higher than those
of the Dox solution and Dox/Complex, which suggested that
Dox/NG was able to maintain a high Dox concentration in the
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Figure 5 | Tumour targetability and antitumour activity. (a) In vivo fluorescence imaging of the MDA-MB-231 tumour-bearing nude mice at 1, 6 and
24h after intravenous injection of Dox/Cy5.5-Complex (I), Dox/Cy5.5-NG (II) and Dox/Cy5.5-NG with pre-injection of free HA (III) at Cy5.5 dose of
30 nmol kg 1. Arrows indicate the sites of tumours. (b) Ex vivo fluorescence imaging of the tumour and normal tissues harvested from the euthanized
MDA-MB-231 tumour-bearing nude mice at 24 h post injection. The numeric label for each organ is as follows: 1, heart; 2, liver; 3, spleen; 4, lung; 5, kidney;
6, tumour. (c) Region-of-interest analysis of fluorescent signals from the tumours and normal tissues. Error bars indicated s.d. (n¼ 3). *Po0.05 (two-tailed
Student’s t-test). (d) The MDA-MB-231 tumour growth curves after intravenous injection of different formulations of Dox at a dose of 2mg kg 1.
Error bars indicate s.d. (n¼ 5). *Po0.05, **Po0.01 (two-tailed Student’s t-test). (e) Representative images of the MDA-MB-231 xenograft tumours of the
mice after treatment with the studied Dox formulations at Day 14. Arrows indicate the sites of tumours. (f) The body weight variation of MDA-MB-231
tumour-bearing mice during treatment. Error bars indicate s.d. (n¼ 5). (g) Histological observation of the tumour tissues after treatment. The tumour
sections were stained with hematoxylin and eosin. Scale bar is 100 mm. (h) Detection of apoptosis in the tumour tissues after treatment. The tumour
sections were stained with fluorescein-dUTP (green) for apoptosis and Hoechst for nuclei (blue). Scale bar is 200mm.
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systemic circulation within a prolonged period. In addition,
Dox/NG rendered higher Dox accumulation in the tumour
tissues compared with the Dox solution and Dox/Complex
(Supplementary Fig. 14). The Dox amount in the tumour tissues
delivered by Dox/NG was 4.19- and 3.94-fold that of those
delivered by the Dox solution and Dox/Complex at 24 h post
injection. It was validated that the ATP-responsive nanogels had
high tumour targetability due to a combination of passive and
active targeting mechanisms.
Next, the antitumour efficacy of Dox/NG was estimated in
MDA-MB-231 tumour xenograft models. As shown in Fig. 5d,
different Dox formulations had significant effects on inhibiting
tumour growth compared with saline as a negative control after
successive intravenous administration into the tumour-bearing
mice. Both Dox/cNG and Dox/NG presented remarkably higher
inhibition efficacy towards tumour growth than the Dox solution,
which primarily resulted from the tumour targeting capability of
these nanogels. More importantly, a noticeable difference in
tumour-size inhibition between Dox/NG and Dox/cNG was
observed (Fig. 5d,e), suggesting that the efficient intracellular
delivery and ATP-triggered Dox release are of great importance
to enhanced antitumour activity. The body weights of the mice
had no significant change during the treatment of Dox/NG
(Fig. 5f). The histologic images using hematoxylin and eosin
staining showed that after applying Dox/NG, a massive cancer
cell remission occurred in the tumour tissue (Fig. 5g) while
producing no obvious pathological abnormalities in the heart,
such as cardiomyopathy, the main toxic effect in Dox cancer
treatment50 (Supplementary Fig. 15). Moreover, the images
obtained using the in situ TUNEL assay showed the highest
level of cell apoptosis in the tumour harvested from the mice
treated with Dox/NG (Fig. 5h), indicating that the dominant
inhibition activity of tumour growth was attributable in part to
the increased apoptosis effect induced by Dox/NG. Collectively,
these results verified that ATP-responsive Dox/NG efficiently
accumulated at the tumour site, demonstrated effective
intracellular transport and ATP-mediated drug release, and
thereby achieved optimal antitumour efficacy in vivo.
Discussion
We have developed an ATP-responsive anticancer DDS consist-
ing of a nanogel with DNA, protein and polysaccharide. Our
nanocarriers show drug release properties correlated to ATP
levels, which selectively release the encapsulated Dox at high ATP
levels for enhanced biological specificity and therapeutic efficacy
in cancer therapy. We anticipate that this strategy will provide
new opportunities for utilizing ATP as a metabolic trigger, which
can lead to the development of increasingly specific DDS.
Here Dox was intercalated in the GC-rich pairs of the DNA
motif; however, other drugs51–53 could also be loaded into the
DNA chain through their specific affinity and be released by
ATP’s invasion. Alternatively, drugs can be encapsulated into
nanocarriers ‘caged’ by ATP aptamer for reversibly controlling
drug release on ATP’s trigger. Furthermore, the intracellular level
of ATP can be tuned by directly delivering ATP molecule54,55 or
adjusting other metabolic elements’ concentration or activity,
such as glucose level, hydrogen ion gradient and oxidative
stress56–58.
Methods
Materials. All chemicals were purchased from Sigma-Aldrich unless otherwise
specified, and were used as received. Hyaluronic acid (HA, 77 kDa) was purchased
from Freda Biochem Co., Ltd. (Shandong, China). ATP aptamer, single-stranded
cDNA of ATP aptamer, control aptamer, cDNA of control aptamer and
Cy5.5-labelled cDNA of ATP aptamer were purchased from Integrated DNA
Technologies, Inc. (Coralville, USA).
Preparation and characterization of Dox-loaded nanogels. Hundred microlitres
of m-protamine (0.7mgml 1) was mixed with 100 ml of Dox/Duplex
(0.85mgml 1) and incubated for 10min. The complex (Dox/Complex) was added
into 200 ml of m-HA (0.35mgml 1) solution with stirring, followed by adding
glycerol dimethacrylate (GDA) (0.07mg). Radical polymerization was photo-
initiated by Irgacure 2959 (0.1%, w:v) under the exposure to the ultraviolet
radiation at the intensity of c.a. 20mV cm 2 for 60 s using a BlueWave 75 UV
Curing Spot Lamp (DYMAX). Finally, the resulting Dox-loaded nanogels
(Dox/NG) were obtained by washing with nuclease-free water using centrifugal
filter units (3 K MWCO) (Millipore) to remove the excessive crosslinker and
initiator. Dox/Cy5.5-NG was obtained by the same method described above, except
that Cy5.5-labelled duplex (Cy5.5-Duplex) hybridized by ATP aptamer and
Cy5.5-labelled cDNA were added into the components of the nanogels to achieve a
final Cy5.5 concentration of 5 mM in Dox/Cy5.5-NG. The particle size and zeta
potential were measured by the Zetasizer (Nano ZS, Malvern). For TEM
characterization, Dox/NG was dropped onto a TEM copper grid (300 mesh) (Ted
Pella) and then stained with 1% (w:v) phosphotungstic acid for 1min. After air dry,
the sample was observed by TEM (JEM-2000FX, Hitachi) operating at 80 kV.
In vitro ATP-triggered Dox release. Dox/NG (0.5ml) with 14mg of Dox was
added into a dialysis tube (10 K MWCO) (Slide-A-Lyzer, Thermo Scientific)
against 14ml of the HEPES buffer solution (5mM HEPES, 10mM MgCl2, 137mM
NaCl) containing different concentrations of ATP, and gently shaken at 37 C in a
shaker (New Brunswick Scientific) at 100 r.p.m. At predetermined time intervals,
the total buffer solution was withdrawn, followed by replacing with 14ml of fresh
buffer solution with the same ATP concentration. The fluorescence intensity of
Dox released was measured at 596 nm with an excitation wavelength of 480 nm by
a microplate reader (Infinite M200 PRO, Tecan).
Cell culture. MDA-MB-231 and MCF-7 cells were obtained from Tissue Culture
Facility of UNC Lineberger Comprehensive Cancer Center and cultured in DMEM
with 10% (v:v) fetal bovine serum (FBS), 100Uml 1 penicillin and 100mgml 1
streptomycin in an incubator (Thermo Scientific) at 37 C under an atmosphere of
5% CO2 and 90% relative humidity. The cells were sub-cultivated approximately
every 3 days at 80% confluence using 0.25% (w:v) trypsin at a split ratio of 1:5.
ATP-dependent Dox release in the cells. MDA-MB-231 cells (1 105 cells per
well) were seeded in six-well plates. After culture for 48 h, the cells were incubated
with Dox-loaded nanogels (2mM Dox concentration) for 2 h at 37 C. Then, the
excessive nanogels were removed and the cells were incubated with fresh FBS-free
culture medium at 37 C for additional 2 h or 4 h. After washing the cells by 4 C
PBS twice, the fluorescence intensity of Dox in the cells were measured using flow
cytometry (BD FACSCalibur). Low temperature (4 C) and IAA were used to
inhibit ATP production in the cells. The content of ATP in the cells was assayed by
the ATPlite Assay Kit (Perkin Elmer). After cell incubation with Dox/NG (2 mM
Dox concentration) for 2 h at 37 C, the excessive nanogels were removed and the
cells were incubated at 4 C or with IAA (100 mM) at 37 C for additional 2 h or 4 h.
After washing the cells by 4 C PBS twice, the fluorescence intensity of Dox in the
cells was measured using flow cytometry (BD FACSCalibur).
Intracellular trafficking. MDA-MB-231 cells (1 105 cells per well) were seeded
in a confocal microscopy dish (MatTek). After culture for 24 h, the cells were
incubated with Dox/NG (2 mM Dox concentration) at 37 C for 2 h, and then
washed by 4 C PBS twice, followed by incubation with fresh FBS-free culture
medium for additional 0 h or 4 h. Subsequently, the cells were stained by Lyos-
Tracker Green (50 nM) (Life Technologies) at 37 C for 30min and Hoechst 33342
(1 mgml 1) (Life Technologies) at 37 C for 10min. Finally, the cells were washed
by 4 C PBS twice and immediately observed using CLSM (LSM 710, Zeiss).
In vitro cytotoxicity. MDA-MB-231 or MCF-7 cells (1 104 cells per well) were
seeded in 96-well plates. After culture for 24 h, the cells were exposed to the Dox
solution and Dox-loaded nanogels with different concentrations of Dox for 24 h,
followed by adding 20ml of the MTT solution (5mgml 1). After 4 h of incubation,
the medium was removed, and the cells were mixed with 150 ml of dimethyl
sulphoxide. The absorbance was measured at a test wavelength of 570 nm and a
reference wavelength of 630 nm by a microplate reader (Infinite M200 PRO,
Tecan).
Apoptosis assay. Apoptosis of MDA-MB-231 cells was detected using the
APO-BrdU TUNEL Assay Kit (Life Technologies) and Annexin V-FITC Apoptosis
Detection Kit (BD Biosciences). The cells (1 105 cells per well) were seeded in
six-well plates. After culture for 48 h, the cells were incubated with Dox-loaded
nanogels for 12 h (Annexin V-FITC) or 20 h (TUNEL). The subsequent procedures
were performed in accordance with the manufacturer’s protocol. For Annexin
V-FITC apoptosis detection, the cells were analysed by flow cytometry (BD
FACSCalibur), while for TUNEL assay the cells were observed by fluorescence
microscope (IX71, Olympus).
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Animals and tumour xenograft models. All animals were treated in accordance
with the Guide for Care and Use of Laboratory Animals, approved by the
Institutional Animal Care and Use Committee (IACUC) of North Carolina State
University. To set up the tumour xenograft model, the female nude mice (6 weeks,
J:NU, The Jackson Laboratory) were subcutaneously inoculated in the back with
1 107 MDA-MB-231 cells. The tumour size was monitored by a vernier caliper
and the tumour volume (V) was calculated as V¼ LW2/2, where L and W were
the length and width of the tumour, respectively.
In vivo imaging study. When the tumours reached to 200–400mm3, the mice
were intravenously injected by Dox/Cy5.5-Complex and Dox/Cy5.5-NG at
Cy5.5 dose of 30 nmol kg 1. For HA competitive study, the mice were pre-injected
by a high dose of free HA (50mg kg 1), and after 30min were injected by
Dox/Cy5.5-NG. Images were taken on IVIS Lumina imaging system (Caliper,
USA) at 1, 6 and 24 h post injection. After the 24 h scanning, the mice were
euthanized. The tumours as well as major organs were harvested, weighed and
subjected for ex vivo imaging. Region-of-interests were circled around the organs,
and the fluorescence intensities were analysed by Living Image Software.
In vivo antitumour efficacy. The tumour-bearing mice were weighed and
randomly divided into different groups when the tumour volume reached to
50mm3. From Day 0, the mice were intravenously injected with Dox solution
(2mg kg 1), Dox-loaded nanogels (2mg kg 1) and saline as a negative control
every other day for 12 days, and meanwhile the tumour size was measured. At Day
14, the mice were euthanized, and the tumour as well as the heart were collected,
weighed, washed with saline thrice and fixed in the 10% neutral-buffered formalin.
For the hematoxylin and eosin staining, the formalin-fixed tumours and hearts
were embedded in paraffin blocks and visualized by optical microscope (DM5500B,
Leica). For the TUNEL apoptosis staining, the fixed tumour sections were stained
by the In Situ Cell Death Detection Kit (Roche Applied Science) according to the
manufacturer’s protocol. Hoechst 33342 was used for nuclear counterstaining. The
stained tumour slides were observed by fluorescence microscope (IX71, Olympus).
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